Trial · NCT07525466
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
NCT07525466, Phase 1, Phase 2, Recruiting, Beijing Tongren Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH). Trials, record NCT07525466. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07525466
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
- NCT number
- NCT07525466
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Beijing Tongren Hospital
- Conditions
- Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)
- Interventions
- Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase, methylprednisolone, golidocitinib
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month overall survival (OS) rate | From the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G | OS was defined from the date of initiation of MEPL-G to the date fo death. |
| Secondary | 6-month progression free survival (PFS) rate | From the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G | PFS was defined from the date of initiation of MEPL-G to the date of confirmed disease progression or death of any reason |
| Secondary | overall response rate (ORR) | from the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G. | Overall response rate means sum of complete response rate and partial response rate |
| Secondary | complete response (CR) rate | from the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G. | CR was defined as complete response evaluated using PET-CT scan |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | from the date of initiation of MEPL-G as of 6 months after initiation of MEPL-G | measured using CTCAE version 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07525466
GET https://conductscience.org/api/trials/v1/NCT07525466/registered